Cocrystal Pharma
COCP
35 hedge funds and large institutions have $13.5M invested in Cocrystal Pharma in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
13% more funds holding
Funds holding: 31 → 35 (+4)
0.1% less ownership
Funds ownership: 1.24% → 1.14% (-0.1%)
2% less capital invested
Capital invested by funds: $13.8M → $13.5M (-$310K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$516K |
| 2 |
LPL Financial
San Diego,
California
|
+$235K |
| 3 |
Goldman Sachs
New York
|
+$89.6K |
| 4 |
Squarepoint
New York
|
+$77.4K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$73.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.36M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$140K |
| 3 |
Millennium Management
New York
|
-$29K |
| 4 |
Jane Street
New York
|
-$16K |
| 5 |
PA
Parallel Advisors
San Francisco,
California
|
-$14.4K |
COCP Hedge Fund Activity: Q1 2021 in Review
35 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q1 2021, worth a combined $13.5M — down 2.2% from $13.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new COCP positions and 6 closed out — a net gain of 4 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $516K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.36M sold.
- 35 institutional investors held Cocrystal Pharma (COCP) as of Q1 2021, up from 31 in Q4 2020.
- Funds reported $13.5M of Cocrystal Pharma stock for Q1 2021, down 2.2% quarter-over-quarter.
- 10 funds opened new Cocrystal Pharma positions in Q1 2021 and 6 closed out, a net change of +4 holders.
- The largest Cocrystal Pharma buyer in Q1 2021 was Renaissance Technologies, an estimated $516K added.
- The largest Cocrystal Pharma seller in Q1 2021 was Point72 Asset Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q1 2021.